Table 2.

Percentage change from baseline in lipid variables at 16 weeks (ITT population). Doses were titrated from week 4 to week 16 in patients who had not reached the 1998 European LDL-C goal (< 3.0 mmol/L)

Variable	Least-squares mean percentage change from baseline to 16 weeks		Difference (95% CI)	p-value
	Rosuvastatin 10–40 mg (n = 221)	Atorvastatin 10–80 mg (n = 220)
LDL-C	-52.3	-45.5	-6.7 (-8.8, -4.7)	< 0.0001
TC	-35.4	-31.3	-4.1 (-5.8, -2.4)	< 0.0001
HDL-C	5.3	4.0	1.3 (-1.3, 3.8)	NS
TG	-21.2	-21.1	-0.1 (-5.6, 5.3)	NS
Non-HDL-C	-45.0	-39.6	-5.5 (-7.4, -3.5)	< 0.0001
LDL-C/HDL-C ratio	-54.1	-47.0	-7.1 (-9.3, -4.9)	< 0.0001
Non-HDL-C/HDL-C ratio	-47.1	-40.9	-6.2 (-8.6, -3.9)	< 0.0001
TC/HDL-C ratio	-38.0	-33.1	-5.0 (-6.9, -3.0)	< 0.0001
Apo B	-45.2	-40.1	-5.1 (-7.2, -3.1)	< 0.0001
Apo A-I	2.6	-0.2	2.8 (1.0, 4.6)	0.0024
Apo B/apo A-I ratio	-46.3	-39.6	-6.7 (-8.9, -4.6)	< 0.0001

ITT: Intention to treat, CI: Confidence interval, LDL-C: Low-density lipoprotein cholesterol, TC: Total cholesterol, HDL-C: High-density lipoprotein cholesterol, TG: Triglycerides, Apo: Apolipoprotein, NS: Not statistically significant